Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
- Registration Number
- NCT02947815
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Brief Summary
The purpose of this study is to evaluate the Efficacy and Safety of NABOTA in treatment of essential blepharospasm
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 234
Inclusion Criteria
- Male of female of at least 18 years old
- Grade 2~4 in Scott's scale
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BOTOX Clostridium Botulinum Toxin Type A Single-dose NABOTA Clostridium Botulinum Toxin Type A Single-dose
- Primary Outcome Measures
Name Time Method The change from baseline in Scott's Scale Score At 4 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of NABOTA in treating essential blepharospasm compared to BOTOX?
How does NABOTA's efficacy compare to BOTOX in reducing blepharospasm severity scores?
Are there specific biomarkers that predict response to botulinum toxin A in blepharospasm patients?
What adverse events are associated with NABOTA versus BOTOX in facial muscle disorder treatments?
What is the therapeutic landscape for botulinum toxin alternatives in managing essential blepharospasm?
Trial Locations
- Locations (1)
the catholic university of korea, Seoul ST. Mary's Hospital.
🇰🇷Seoul, Korea, Republic of
the catholic university of korea, Seoul ST. Mary's Hospital.🇰🇷Seoul, Korea, Republic of